In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...
Hosted on MSN4d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate ...
However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback